The use of probiotics in reducing inflammation caused by metabolic syndrome: an integrative review




Inflammation mediators; Metabolic Syndrome; Probiotics.


The Metabolic Syndrome (MS) represents a condition of pro-thrombotic and pro-inflammatory state characterized by increased inflammatory activity of cytokines. Dysbiosis processes have been associated with obesity, present in MS, so the use of probiotics has been considered as an alternative to traditional approaches to weight loss and a low-calorie diet, provided they are consumed in adequate amounts. This is an integrative literature review, whose guiding question “Does the use of probiotics reduce the inflammation generated by the metabolic syndrome?” induced the research carried out in the databases: SCIELO, VHL, PUBMED and Science Direct. The descriptors “inflammation”, “probiotic”, “metabolic syndrome” and “insulin resistance” were used. The articles were analyzed using the PRISMA model, and 8 articles were included in the final sample for review. All included studies were published in the year 2017 to 2022 in English. The probiotic effect on body weight is dependent on a number of factors, such as the species and strains of microorganisms and the time of administration of the probiotic. Some of them have been widely used in patients with MS to reduce the inflammatory state of the body, acting mainly in reducing body weight, BMI, waist and hip circumferences, systolic and diastolic blood pressure. In addition, there was a reduction in pro-inflammatory markers such as interleukin 5 and C-reactive protein with the use of probiotics. These findings justify the need for multicentric research, with a heterogeneous population to be analyzed in order to accurately determine the therapeutic effects of probiotics in reducing inflammatory markers and cardiometabolic risk factors in patients with MS.


Andriani, N., Quessada, L., Quessada, L., Camporeze, B., Soffiatti, F., & Guastalli, G. (2018). Inter-Relação Entre Microbiota Intestinal E Síndrome Metabólica: Futuro Tratamento Promissor. International Journal of Nutrology.

Araújo, L. M. B., Britto, M. M. dos S., & Porto da Cruz, T. R. (2000). Tratamento do diabetes mellitus do tipo 2: novas opções. Arquivos Brasileiros de Endocrinologia & Metabologia, 44(6), 509–518.

Barbalho, S. M., Bechara, M. D., Quesada, K., Gabaldi, M. R., Goulart, R. de A., Tofano, R. J., & Gasparini, R. G. (2015). Síndrome metabólica, aterosclerose e inflamação: tríade indissociável? Jornal Vascular Brasileiro, 14(4), 319–327.

Brancher, J. S. (2014). Uso de probióticos no tratamento da obesidade: uma revisão sistemática [Trabalho de Conclusão de Curso (Bacharel em Nutrição)].

Cheng, A. Y. Y. (2005). Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian Medical Association Journal, 172(2), 213–226.

Cicero, A. F. G., Fogacci, F., Bove, M., Giovannini, M., & Borghi, C. (2021). Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. European Journal of Nutrition, 60(2), 655–663.

Depommier, C., Everard, A., Druart, C., Maiter, D., Thissen, J.-P., Loumaye, A., Hermans, M. P., Delzenne, N. M., de Vos, W. M., & Cani, P. D. (2021). Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome. Gut Microbes, 13(1).

Grandl, G., & Wolfrum, C. (2018). Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Seminars in Immunopathology, 40(2), 215–224.

Kazemi, A., Soltani, S., Ghorabi, S., Keshtkar, A., Daneshzad, E., Nasri, F., & Mazloomi, S. M. (2019). Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clinical Nutrition, 39(3).

Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019). Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 9(3), e017995.

McCracken, E., Monaghan, M., & Sreenivasan, S. (2018). Pathophysiology of the metabolic syndrome. Clinics in Dermatology, 36(1), 14–20.

Nunes, M. L., & Garrido, M. P. (2019). A obesidade e a ação dos prebióticos, probióticos e simbióticos na microbiota intestinal. Nutrição Brasil, 17(3), 189–196.

Penalva, D. Q. F. (2008). Síndrome metabólica: diagnóstico e tratamento. Revista de Medicina, 87(4), 245.

Rabiei, S., Hedayati, M., Rashidkhani, B., Saadat, N., & Shakerhossini, R. (2018). The Effects of Synbiotic Supplementation on Body Mass Index, Metabolic and Inflammatory Biomarkers, and Appetite in Patients with Metabolic Syndrome: A Triple-Blind Randomized Controlled Trial. Journal of Dietary Supplements, 16(3), 294–306.

Rezazadeh, L., Alipour, B., Jafarabadi, M. A., & Gargari, B. P. (2020). Evaluation of the effects of probiotic yoghurt on inflammation and cardiometabolic risk factors in subjects with metabolic syndrome: A randomised controlled trial. International Dairy Journal, 101, 104577.

Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017). Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease, 11(8), 215–225.

Samson, S. L., & Garber, A. J. (2014). Metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 43(1), 1–23.

Sato, J., Kanazawa, A., Azuma, K., Ikeda, F., Goto, H., Komiya, K., Kanno, R., Tamura, Y., Asahara, T., Takahashi, T., Nomoto, K., Yamashiro, Y., & Watada, H. (2017). Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. Scientific Reports, 7(1).

Silva-Júnior, A. do C., Cruz, D. P., Vitório De Souza Junior, E., Souza Rosa, R., Missias Moreira, R., & Santana Cardoso Santos, I. (2020). [Repercussions of the prevalence of metabolic syndrome on adults and elderly people in the context of primary health care]. Revista de Salud Publica (Bogota, Colombia), 20(6), 735–740.

Sociedade Brasileira de Cardiologia. (2005). I Diretriz Brasileira de diagnóstico e tratamento da síndrome metabólica.

Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Integrative review: what is it? How to do it? Einstein (São Paulo), 8(1), 102–106.

Tenorio-Jiménez, C., Martínez-Ramírez, M. J., Del Castillo-Codes, I., Arraiza-Irigoyen, C., Tercero-Lozano, M., Camacho, J., Chueca, N., García, F., Olza, J., Plaza-Díaz, J., Fontana, L., Olivares, M., Gil, Á., & Gómez-Llorente, C. (2019). Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients, 11(8), E1761.



How to Cite

ARRUDA, M. P. de S.; OLIVEIRA, M. B. de P.; RASERA JR, I. The use of probiotics in reducing inflammation caused by metabolic syndrome: an integrative review. Research, Society and Development, [S. l.], v. 11, n. 14, p. e270111436242, 2022. DOI: 10.33448/rsd-v11i14.36242. Disponível em: Acesso em: 7 jun. 2023.



Review Article